Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockGet instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Discovery themes featuring this stockIOL Chemicals & Pharmaceuticals Ltd (IOLCP) is currently trading at 70.55 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
IOL Chemicals and Pharmaceuticals Limited is an integrated API and specialty chemicals manufacturer producing globally significant volumes of Ibuprofen, Ethyl Acetate, Acetic Anhydride and multiple APIs from an 11‑unit, 180+ acre complex; the company services ~80 countries and combines chemical intermediates with regulated API production across dedicated and multiproduct blocks. The company uniquely claims to be the world’s only fully backward integrated Ibuprofen producer with 12,000 MT annual capacity, and has materially diversified its pharma mix: non‑Ibuprofen share rose from 18% to 34% over five years, reducing concentration risk and improving revenue quality with multiple regulatory filings across USFDA, EDQM and ANVISA. Recent financial momentum: Q3 FY26 revenue was INR580.4 crore (+10.9% YoY) and 9M revenue INR1,699.6 crore (+9.6% YoY), with 9M EBITDA margin improving to 11.4% and PBT growth of 34.2% pre‑exceptional; balance sheet strength is notable with net low leverage (debt‑equity ~0.07) and healthy operating cash generation supporting ongoing capex. Strategic expansion is visible and actionable: Unit 11 paracetamol (10,800 MTPA) is operational, clopidogrel capacity increased, and a 101‑acre land parcel has been acquired for future development; management plans sustained capex (~INR150–200 crore pa) to scale regulated market exports toward a target ~40% contribution. IOL’s regulatory and R&D credentials underpin growth: DSIR‑approved R&D with 50+ scientists, 15 US DMFs, 21 CEP filings (19 approved), ANVISA and multiple global certifications provide a pathway to accelerate sales into regulated markets and commercialize nine pipeline products.
Over the past 52 weeks, IOL Chemicals & Pharmaceuticals Ltd has traded between a low of ₹57.51 and a high of ₹126.60. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
IOL Chemicals & Pharmaceuticals Ltd has a market capitalization of approximately 2,058.80. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
IOL Chemicals & Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 17.86 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 2,058.80 Cr, IOL Chemicals & Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
IOL Chemicals & Pharmaceuticals Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of IOL Chemicals & Pharmaceuticals Ltd is 17.86. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Bearish
4
Neutral
4
Bullish
6
Bearish
35
Neutral
4
Bullish
7
Bearish
31
Neutral
0
Bullish
1
IOL Chemicals and Pharmaceuticals Limited is an integrated API and specialty chemicals manufacturer producing globally significant volumes of Ibuprofen, Ethyl Acetate, Acetic Anhydride and multiple APIs from an 11‑unit, 180+ acre complex; the company services ~80 countries and combines chemical intermediates with regulated API production across dedicated and multiproduct blocks.
The company uniquely claims to be the world’s only fully backward integrated Ibuprofen producer with 12,000 MT annual capacity, and has materially diversified its pharma mix: non‑Ibuprofen share rose from 18% to 34% over five years, reducing concentration risk and improving revenue quality with multiple regulatory filings across USFDA, EDQM and ANVISA.
Recent financial momentum: Q3 FY26 revenue was INR580.4 crore (+10.9% YoY) and 9M revenue INR1,699.6 crore (+9.6% YoY), with 9M EBITDA margin improving to 11.4% and PBT growth of 34.2% pre‑exceptional; balance sheet strength is notable with net low leverage (debt‑equity ~0.07) and healthy operating cash generation supporting ongoing capex.
Strategic expansion is visible and actionable: Unit 11 paracetamol (10,800 MTPA) is operational, clopidogrel capacity increased, and a 101‑acre land parcel has been acquired for future development; management plans sustained capex (~INR150–200 crore pa) to scale regulated market exports toward a target ~40% contribution.
IOL’s regulatory and R&D credentials underpin growth: DSIR‑approved R&D with 50+ scientists, 15 US DMFs, 21 CEP filings (19 approved), ANVISA and multiple global certifications provide a pathway to accelerate sales into regulated markets and commercialize nine pipeline products.
Pharmaceuticals
Pharmaceuticals - Indian - Bulk Drugs & Formln M/S
2,059 Cr
High Risk
17.9
27.5
0.8
1.2
126.60
57.51
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
164.50 | 2,574 Cr | 21.73 | 0.40 | 0.00 | 2.14 | 3.12 | 1.07 | |
920.55 | 2,273 Cr | 23.37 | 2.93 | 2.71 | 13.75 | 17.93 | 10.43 | |
320.00 | 2,264 Cr | 7.66 | 0.93 | 0.00 | 5.98 | 6.30 | 8.29 | |
40.75 | 2,233 Cr | 22.64 | 1.87 | 0.49 | 6.31 | 8.14 | 5.77 | |
70.55 | 2,059 Cr | 17.86 | 1.18 | 1.14 | 6.62 | 9.15 | 4.80 | |
458.55 | 2,016 Cr | -95.38 | 1.34 | 0.00 | 0.51 | 5.47 | -0.83 | |
198.00 | 1,823 Cr | -15.70 | 1.86 | 0.10 | -11.28 | -2.11 | -4.64 |
